All In Biotech

Drug Trial Radar · NCT03222583

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

Last checked: Nov 20, 2026Latest source record: Dec 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 546 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

546

Actual

Start

Oct 4, 2017

Primary completion

Oct 18, 2018

Study completion Feb 15, 2019

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) with or without ribavirin (RBV), OR sofosbuvir with RBV with or without IFN.

Conditions

  • Hepatitis C Virus (HCV)

Interventions

  • PlaceboDrug

    Matching placebo tablet for oral administration

  • Glecaprevir/PibrentasvirDrug

    Coformulated tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12)Time frame: 12 weeks after the last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen.
  2. Percentage of HCV GT1-Infected Participants in Arm A Who Achieved SVR12Time frame: 12 weeks after last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen
  3. Percentage of HCV GT2-Infected Participants in Arm A Who Achieved SVR12Time frame: 12 weeks after the last dose of study drug, Week 20 or Week 28 depending on the treatment regimen.

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • Beijing Di Tan Hospital, Capital Medical University /ID# 156847

    Beijing, China

  • 1st Hospital of Peking Uni /ID# 156845

    Beijing, China

  • 302 Military Hospital Of China /ID# 156841

    Beijing, China

  • Beijing Friendship Hospital /ID# 156840

    Beijing, China

  • Beijing Youan Hosp, Cap Med Un /ID# 163430

    Beijing, China

  • 1st Affiliated Hosp 3rd Milita /ID# 156831

    Chongqing, China

  • Dalian Sixth Peoples Hospital /ID# 163433

    Dalian, China

  • Mengchao Hepatobiliary Hospita /ID# 156902

    Fuzhou, China

  • Hainan General Hospital /ID# 156839

    Haikou, Hainan, China

  • Jinan Infectious Diseases Hosp /ID# 156886

    Jinan, Shandong, China

  • Chinese People's Liberation Army 81 Hospital /ID# 156862

    Nanjing, China

  • Shengjing Hospital of China Medical University /ID# 156824

    Shenyang, China

  • Tianjin Third Central Hospital /ID# 156816

    Tianjin, China

  • 1st Aff Hosp Xinjiang Med Uni /ID# 156887

    Ürümqi, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 156884

    Wuhan, China

  • Tongji Hosp Tongji Med College /ID# 156885

    Wuhan, China

  • Fourth Military Medical University Tangdu Hospital, PLA /ID# 156765

    Xi'an, China

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University /ID# 163432

    Xi'an, China

  • Henan Provincial Peoples Hosp /ID# 157197

    Zhengzhou, Henan, China

  • Peking University Peoples Hospit /ID# 156846

    Beijing, Beijing Municipality, China

  • Guangzhou Eighth People's Hosp /ID# 156859

    Guangzhou, Guangdong, China

  • Guangdong General Hospital /ID# 156822

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University /ID# 156860

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 156900

    Guangzhou, Guangdong, China

  • Xiangya Hospital Central South University /ID# 156901

    Changsha, Hunan, China

  • The Second Hospital of Nanjing /ID# 156863

    Nanjing, Jiangsu, China

  • Jiangsu Province People's Hospital /ID# 156861

    Nanjing, Jiangsu, China

  • The First Hosp of Jilin Univ /ID# 156820

    Changchun, Jilin, China

  • The Sixth People's Hospital of Shenyang /ID# 156849

    Shenyang, Liaoning, China

  • Shanghai Changzheng Hospital /ID# 158072

    Shanghai, Shanghai Municipality, China

  • Ruijin Hospital, Shanghai Jiaotong /ID# 157336

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital of Fudan University /ID# 156904

    Shanghai, Shanghai Municipality, China

  • Shanghai Public Health Cli Ctr /ID# 156832

    Shanghai, Shanghai Municipality, China

  • West China Hospital /ID# 156830

    Chengdu, Sichuan, China

  • National University Hospital ( /ID# 163272

    Singapore, Singapore

  • Singapore General Hospital /ID# 163271

    Singapore, Singapore

  • Changi General Hospital /ID# 163270

    Singapore, Singapore

  • Seoul National University Hospital /ID# 163348

    Seoul, South Korea

  • Asan Medical Center /ID# 163336

    Seoul, South Korea

  • Pusan National University Hosp /ID# 163371

    Busan, Busan Gwang Yeogsi, South Korea

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.